Roche obtains CE mark for first blood-based ApoE4 Alzheimer’s test

SWITZERLAND—Swiss pharmaceutical giant Roche has secured CE Mark approval for its Elecsys® Apolipoprotein E4 biomarker test, marking a significant advancement in Alzheimer’s disease diagnostics.

The test represents the first in-vitro diagnostic immunoassay capable of detecting the ApoE4 gene variant directly from a blood sample.

The ApoE4 variant plays a crucial role in Alzheimer’s risk assessment, as it appears in approximately 40–60% of patients diagnosed with the disease.

Scientists have long recognized this genetic marker as a key indicator of increased susceptibility to late-onset Alzheimer’s disease.

Addressing a growing global health crisis

Alzheimer’s disease drives up to 70% of dementia cases worldwide, presenting healthcare systems with mounting challenges.

Current projections estimate that nearly 150 million people will live with the condition by 2050, underscoring the urgent need for improved diagnostic tools.

Simplifying the diagnostic journey

Traditional methods for confirming ApoE4 carrier status have relied on molecular DNA testing, which requires more complex procedures.

Roche’s new test transforms this process by using a minimally invasive blood sample to determine whether an individual carries the ApoE4 variant.

This streamlined approach allows clinicians to efficiently filter out non-carriers, reserving comprehensive genetic testing for patients who genuinely require it.

Patients identified as carriers through the blood test can proceed to follow-up genetic testing for confirmation and additional insights.

This tiered approach proves particularly valuable as disease-modifying therapies increasingly depend on a patient’s specific genetic profile for optimal treatment decisions.

Clinical impact and integration

Matt Sause, CEO of Roche Diagnostics, emphasized the test’s significance in clinical practice. He noted that the approval provides clinicians with a simple and accessible tool for identifying genetic risk factors and guiding treatment strategies.

The test enables rapid identification and triage of ApoE4 carriers among patients experiencing cognitive decline, streamlining both diagnosis and ongoing patient management.

The Elecsys ApoE4 test complements Roche’s existing portfolio of blood-based Alzheimer’s biomarkers.

The recently CE-marked Elecsys pTau181 test assesses key proteins associated with the disease, working alongside the ApoE4 test to provide comprehensive diagnostic insights.

Together, these biomarkers help clinicians detect Alzheimer’s earlier and make evidence-based decisions throughout the patient care journey.

Ensuring broad accessibility

Healthcare providers can perform the Elecsys ApoE4 test using a single blood sample, allowing seamless integration into existing diagnostic workflows.

The test’s compatibility with the extensive network of Roche instruments already deployed in countries recognizing the CE mark ensures widespread accessibility.

This scalability positions the plasma-based solution as a practical tool for supporting Alzheimer’s diagnostic pathways across diverse healthcare settings.